Comparing the current results to its competitors, Xenon Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 15.54 %, recorded in the same quarter.
Xenon Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company utilizes trade secrets, internal expertise, technological innovations, and third-party agreements to maintain its competitive position. As of December 31, 2025, it owned or licensed multiple U.S. and foreign patents and pending applications related to its products, including azetukalner. The company competes with pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical testing, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Additionally, smaller or early-stage companies may pose significant competition, particularly through collaborations with larger firms. The company's commercial opportunities may be diminished or eliminated if competitors develop safer, more effective, more convenient, or less expensive products or obtain regulatory approvals more quickly.
Xenon Pharmaceuticals, a leading clinical-stage biopharmaceutical company, announced the awaited topline results from their Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the efficacy and safety of XEN1101 in patients diagnosed with Major Depressive Disorder (MDD). The groundbreaking trial results were shared via a conference call held today at 8:30 am ET. Major Depressive Disorder, commonly known as depression, is a severe mental health condition affecting millions of people worldwide. It is characterized by persistent feelings of sadness, lack of interest or pleasure in activities, and a notable decline in daily functioning. Current available treatments, such as selective serotoni...
Publicly Traded Peers of Xenon Pharmaceuticals Inc
Biomarin Pharmaceutical Inc Share Performance
+2.97%
30 Days
Biomarin Pharmaceutical Inc
Profile
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Sources:
Xenon Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xenon Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
